Drugs Made In America Acquisition Corp. $DMAA Shares Sold by DLD Asset Management LP

DLD Asset Management LP reduced its stake in Drugs Made In America Acquisition Corp. (NASDAQ:DMAA) by 39.8% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 113,672 shares of the company’s stock after selling 75,050 shares during the period. DLD Asset Management LP owned approximately 0.39% of Drugs Made In America Acquisition worth $1,167,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of DMAA. Context Capital Management LLC acquired a new stake in shares of Drugs Made In America Acquisition during the third quarter valued at about $2,568,000. Wolverine Asset Management LLC boosted its position in shares of Drugs Made In America Acquisition by 22.2% during the 3rd quarter. Wolverine Asset Management LLC now owns 1,249,128 shares of the company’s stock worth $12,829,000 after purchasing an additional 227,222 shares during the period. Karpus Management Inc. boosted its position in shares of Drugs Made In America Acquisition by 18.1% during the 2nd quarter. Karpus Management Inc. now owns 2,744,109 shares of the company’s stock worth $27,990,000 after purchasing an additional 420,075 shares during the period. Clear Street LLC acquired a new stake in Drugs Made In America Acquisition in the 2nd quarter valued at approximately $1,149,000. Finally, Boothbay Fund Management LLC acquired a new stake in Drugs Made In America Acquisition in the 2nd quarter valued at approximately $5,814,000.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Drugs Made In America Acquisition in a research note on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has a consensus rating of “Sell”.

Drugs Made In America Acquisition Trading Down 0.2%

Shares of NASDAQ:DMAA opened at $10.47 on Monday. Drugs Made In America Acquisition Corp. has a 1 year low of $9.98 and a 1 year high of $10.49. The firm’s 50-day moving average is $10.42 and its two-hundred day moving average is $10.35.

Drugs Made In America Acquisition Company Profile

Drugs Made In America Acquisition Corp (NASDAQ: DMAA) is a special purpose acquisition company incorporated in Delaware with the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company’s stated focus is on identifying and acquiring one or more operating businesses in the U.S. pharmaceutical sector, particularly those involved in the domestic manufacturing of approved drugs, active pharmaceutical ingredients or related contract development and manufacturing services.

Operating as a blank‐check vehicle, Drugs Made In America Acquisition holds its funds in a trust account pending the completion of an initial business combination.